What is the recommended treatment for non‑alcoholic fatty liver disease?

Treatment of Fatty Liver Disease (NAFLD)

The cornerstone of NAFLD treatment is achieving 5-10% body weight loss through a hypocaloric Mediterranean diet combined with 150-300 minutes of moderate-intensity exercise weekly, with pharmacotherapy reserved for patients with biopsy-proven NASH and significant fibrosis who fail lifestyle interventions 1, 2.

Risk Stratification Determines Treatment Intensity

Treatment should be stratified based on fibrosis risk using FIB-4 score or liver stiffness measurement (LSM):

• Low risk (FIB-4 <1.3 or LSM <8 kPa): Managed in primary care with lifestyle intervention
• Indeterminate risk (FIB-4 1.3-2.67 or LSM 8-12 kPa): Hepatology referral with multidisciplinary management
• High risk (FIB-4 >2.67 or LSM >12 kPa): Hepatology-led care with aggressive intervention 2

Lifestyle Modifications (All Patients)

Weight Loss Strategy

Target 5-10% body weight reduction through calorie deficit. Greater weight loss yields better outcomes: 7-10% reverses steatohepatitis, while 10-15% can reverse fibrosis 1, 2.

Specific dietary approach:

• Mediterranean diet with calorie restriction (most evidence-based pattern) 1, 2
• Reduce refined carbohydrates and processed foods
• Increase vegetables, lean protein, and fish
• Consider referral to structured weight management programs if office-based efforts fail 1

Physical Activity

150-300 minutes of moderate-intensity aerobic exercise weekly (where you can talk but not sing), or 75-150 minutes of vigorous exercise 2. Exercise improves steatosis even without significant weight loss 2.

Alcohol

• Complete abstinence for cirrhotic patients
• Pre-cirrhotic patients should minimize or abstain, as alcohol accelerates progression 1

Pharmacotherapy (Risk-Stratified)

For Patients with Type 2 Diabetes and NASH

Prefer GLP-1 receptor agonists (especially semaglutide) or pioglitazone over other diabetes medications 2:

• Semaglutide has strongest evidence: achieved NASH resolution in 59% vs 17% placebo (0.4 mg daily dose) 2
• Pioglitazone improves steatohepatitis in multiple RCTs 2
• These agents provide dual benefit for glycemic control and liver histology 2

For Non-Diabetic Patients with Biopsy-Proven NASH

Vitamin E 800 IU daily improved steatohepatitis in non-diabetic NASH patients in large randomized trials 2. Evidence is weaker in diabetic patients.

Important Caveat

No FDA-approved medications specifically for NASH exist yet. Pharmacotherapy for NASH cirrhosis should be avoided until more data are available 2.

Bariatric Surgery

Consider referral for bariatric surgery in obese NAFLD patients meeting national eligibility criteria, particularly those with high-risk fibrosis 1, 2. This is increasingly important for patients failing medical management.

Cardiovascular Risk Management (Critical Component)

NAFLD patients have elevated cardiovascular mortality, requiring systematic assessment:

• Annual screening for Type 2 diabetes (HbA1c), hypertension, and dyslipidemia 1
• Use cardiovascular risk scores (e.g., QRISK-3) 1
• Statins should NOT be withheld from NAFLD patients, including those with compensated cirrhosis—hepatotoxicity is very rare and benefits significantly outweigh risks 1, 2
• Manage hypertension per standard guidelines 1
• Offer statin therapy if T2DM present or cardiovascular risk >10% 1

Smoking Cessation

All patients who smoke must be advised to stop and offered referral to cessation services 1.

Surveillance for Advanced Disease

For patients with cirrhosis (F4) or LSM >20 kPa:

• HCC surveillance per national recommendations 1, 2
• Variceal screening if LSM >20 kPa or platelets <150,000/mm³ 2
• Consider Baveno VI criteria to rule out varices requiring treatment 1

Common Pitfalls to Avoid

1. Don't withhold statins due to unfounded hepatotoxicity concerns—they are safe and necessary 1, 2
2. Don't use pharmacotherapy in low-risk patients—lifestyle modification is sufficient 2
3. Don't prescribe NASH medications to cirrhotic patients outside clinical trials—safety data lacking 2
4. Don't forget cardiovascular risk is the leading cause of death in NAFLD, not liver disease 1
5. Don't rely solely on office-based weight loss counseling—structured programs are more effective 2